IOMAI Receives $2.9 Million Grant From NIH for Patch Technology

IOMAI, a private biopharmaceutical company, has announced the award of a $2.9 million grant from NIH to help develop a patch that is designed to improve responses to influenza vaccination. The grant, titled "Immunostimulatory Patch to Enhance Biodefense Vaccines," was made under the National Institute for Allergy and Infectious Disease program, "Cooperative Research for the Development of Vaccines, Adjuvants, Therapeutics, Immunotherapeutics, and Diagnostics for Biodefense and SARS."
Business Wire